A competing risk analysis of hormone therapy interruption in Asian women with breast cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1099-1557|24|3|301-309

ISSN： 1053-8569

Source： PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol.24, Iss.3, 2015-03, pp. : 301-309

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Thiazolidinedione therapy and breast cancer risk in diabetic women: A systematic review and meta‐analysis

By  

DIABETES/METABOLISM: RESEARCH AND REVIEWS (ELECT), Vol. 34, Iss. 2, 2018-02 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Autoimmune diseases and breast cancer risk by tumor hormone‐receptor status among elderly women

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 142, Iss. 6, 2018-03 ,pp. : 1202-1208

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letrozole: advancing hormone therapy in breast cancer

By Lee Rebecca J   Armstrong Anne C   Wardley Andrew M  

Women's Health, Vol. 8, Iss. 6, 2012-11 ,pp. : 611-618

Future Medicine

Access to resources Recommend Favorite

Hormone therapy administration in postmenopausal women and risk of stroke

By Renoux Christel   Suissa Samy  

Women's Health, Vol. 7, Iss. 3, 2011-05 ,pp. : 355-361

Future Medicine

Access to resources Recommend Favorite

Breast-Conserving Therapy for Early-Stage Breast Cancer in Chinese Women: A Meta-Analysis of Case-Control Studies

By  

Oncology Research and Treatment, Vol. 35, Iss. 3, 2012-02 ,pp. : 133-139

Karger

Access to resources Recommend Favorite